drugset / Trial / NCT00661765

A Single Dose Study Investigating the Absorption and Elimination as Well as the Tolerability of Varenicline Transdermal Delivery System (e.g., a Patch) as Compared to Oral Varenicline in Adult Smokers.

NCT00661765

Phase 1 Completed 18 enrolled Pfizer
RandomizedCrossoverOpen-label

Summary

1. To evaluate the absorption and elimination of varenicline Formulation A transdermal delivery system \[TDS (patch)\] compared to varenicline immediate release tablet (CHANTIX®). 2. To evaluate the adhesion of the varenicline Formulation A patch. 3. To evaluate the safety and tolerability of a single application of the varenicline patch and a single oral dose of the varenicline immediate release tablet (CHANTIX®).

Timeline

Start
2008-04
Primary completion
2008-06
Completion
2008-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Varenicline Small molecule 2 mg Oral

Indications

No indication recorded.